Literature DB >> 28463023

When to use belimumab in SLE.

Mariele Gatto1, Luca Iaccarino1, Margherita Zen1, Andrea Doria1.   

Abstract

Entities:  

Keywords:  Acute disease manifestations; belimumab; damage; disease activity; flare rate; systemic lupus erythematosus

Mesh：

Substances：

Year:  2017        PMID： 28463023     DOI： 10.1080/1744666X.2017.1324784

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


× No keyword cloud information.
  6 in total

Review 1.  Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab.

Authors:  Irene Carrión-Barberà; Tarek Carlos Salman-Monte; Sonia Castell; Francisco Castro-Domínguez; Fabiola Ojeda; Jordi Monfort
Journal:  Eur J Rheumatol       Date:  2019-05-20

2.  Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease.

Authors:  Tatsuma Ban; Masako Kikuchi; Go R Sato; Akio Manabe; Noriko Tagata; Kayo Harita; Akira Nishiyama; Kenichi Nishimura; Ryusuke Yoshimi; Yohei Kirino; Hideyuki Yanai; Yoshiko Matsumoto; Shuichi Suzuki; Hiroe Hihara; Masashi Ito; Kappei Tsukahara; Kentaro Yoshimatsu; Tadashi Yamamoto; Tadatsugu Taniguchi; Hideaki Nakajima; Shuichi Ito; Tomohiko Tamura
Journal:  Nat Commun       Date:  2021-07-19       Impact factor: 14.919

Review 3.  Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.

Authors:  Larosa Maddalena; Francesca Trentin; Mariele Gatto; Margherita Zen; Linda Nalotto; Francesca Saccon; Elisabetta Zanatta; Luca Iaccarino; Andrea Doria
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

4.  A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.

Authors:  A Doria; D Bass; A Schwarting; A Hammer; D Gordon; M Scheinberg; N L Fox; J Groark; W Stohl; C Kleoudis; D Roth
Journal:  Lupus       Date:  2018-05-28       Impact factor: 2.911

5.  Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report.

Authors:  Srikanth Mukkera; Maneesh Mannem; Karthik Chamarti; Leela Pillarisetty; Sai Swarupa Vulasala; Lakshmi Alahari; Anusha Ammu; Akshathh Mukkera; Rajeev K Vadlapatla
Journal:  Cureus       Date:  2022-02-26

Review 6.  The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach.

Authors:  Sahar Najafi; Elham Rajaei; Rezvan Moallemian; Forough Nokhostin
Journal:  Clin Rheumatol       Date:  2020-09-03       Impact factor: 3.650
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.